Evgen Pharma PLC Further US Patent Grant (7862A)
March 28 2017 - 8:45AM
UK Regulatory
TIDMEVG
RNS Number : 7862A
Evgen Pharma PLC
28 March 2017
For immediate release 28 March 2017
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Further US Patent Grant
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is pleased to announce that the United States Patent
and Trademark Office ("USPTO") has granted another patent that
extends and reinforces the Company's intellectual property in
connection with sulforaphane, the naturally occurring compound on
which the Company's lead product, SFX-01, is based.
SFX-01 is a synthetic version of sulforaphane and is protected
by extensive composition of matter and manufacturing process
patents. The new patent, granted today under number US9,603,828,
covers a method of isolation and stabilisation of sulforaphane from
a natural source and is strategically important in extending the
Company's intellectual property position.
The patent is entitled Sulforaphane Isolation and Purification
and runs until May 2033. The exclusive worldwide rights to the
patent are held by Evgen Pharma under the terms of a licence
agreement with PharmAgra Labs Inc., the US laboratory that invented
SFX-01.
On 14 February 2017, the Company announced that the USPTO had
granted a patent relating to manufacturing process for SFX-01.
Evgen Pharma has since received a number of Notices of Allowance
across its intellectual property portfolio but has taken the
position that it will only announce material developments in the
major territories of Europe, US and Japan. Developments in other
territories will be summarised in half year and full year financial
reporting.
Evgen Pharma is currently conducting two Phase II trials of
SFX-01, one in advanced breast cancer and one in a type of stroke
called subarachnoid haemorrhage.
Dr Stephen Franklin, CEO of Evgen Pharma, commented: "The
ongoing expansion of our intellectual property position is a
central tenet of our commercialisation strategy. With regard to
SFX-01, we now have granted intellectual property in the US
relating to the composition of the active pharmaceutical ingredient
and the processes for manufacturing. As we move forward, we expect
further developments with the potential to yield a third tier of
patent protection around SFX-01."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Enquiries:
Evgen Pharma plc c/o +44 (0) 20
Dr Stephen Franklin, CEO 7466 5000
www.evgen.com
Buchanan
Mark Court, Sophie Cowles, Stephanie +44 (0) 20
Watson 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney, Margarita
Mitropoulou (Corporate Finance)
John Howes and Rob Rees (Corporate +44 (0) 20
Broking) 3861 6625
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. It is also carrying out preclinical work in
multiple sclerosis and has a clinical interest in prostate cancer.
The Company's core technology is Sulforadex(R), a method for
synthesising and stabilising the naturally occurring compound
sulforaphane and novel proprietary analogues based on sulforaphane.
The lead product, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information please visit: www.evgen.com
For a recent analyst research note on Evgen Pharma, please
visit:
http://www.hardmanandco.com/docs/default-source/company-docs/evgen-pharma-documents/29.11.16-harnessing-the-clinical-potential-of-sulforaphane.pdf
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEADDPADXXEFF
(END) Dow Jones Newswires
March 28, 2017 09:45 ET (13:45 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024